Google
×
Any time
  • Any time
  • Past hour
  • Past 24 hours
  • Past week
  • Past month
  • Past year
Verbatim
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.
Abstract. Background: We previously reported significant associations between genetic variants in insulin receptor substrate 1 (IRS1) and breast cancer.
The objectives of this study were to investigate whether the IRS1 variants modified ovarian cancer risk and were associated with breast cancer risk in a larger ...
The IRS1 Gly972Arg single-nucleotide polymorphism, which affects insulin-like growth factor and insulin signaling, modifies ovarian cancer risk in BRCA1 and ...
Dec 6, 2012 · Correction: A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 ...
People also ask
The objectives of this study were to investigate whether the IRS1 variants modified ovarian cancer risk and were associated with breast cancer risk in a larger ...
It has been speculated that IRS1 variants, which affect IGF and insulin signaling, modify OC risk in breast cancer 1 (BRCA1) and BRCA2 mutation carriers (19) .
A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers ; 1362-1370 · 9.
In summary, the IRS1 Gly972Arg SNP, known to affect both IGF and INS signaling, significantly modifies risk of developing ovarian cancer in both BRCA1 and BRCA2 ...
The objectives of this study were to investigate whether the IRS1 variants modified ovarian cancer risk and were associated with breast cancer risk in a larger ...